Study identifier:D6582C00001
ClinicalTrials.gov identifier:NCT05492877
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2a Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Phase 2
No
AZD4831
All
288
Interventional
40 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jan 2023 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Placebo Approximately 144 participants will be randomised to receive placebo. | Other: Placebo Oral dosage, once daily. Other Name: N/A |
Experimental: AZD4831 Approximately 144 participants will be randomised to receive AZD4831. | Drug: AZD4831 Oral dosage, once daily. Other Name: N/A |